Objective. The Affordable Care Act mandates the Prospective Payment System (PPS)-Exempt Cancer Hospitals Quality Reporting program. These 11 hospitals (which are paid fee-for-service rather than on a DRG system) began reporting measures (2 general safety, 2 breast, 1 colon) in 2013. Given this reporting mandate, we set out to determine whether the PPS-exempt gynecologic oncology programs could identify quality measures specific to the care of our patients.
Introduction
While tempting to assume that the substantial increased spending on health care (projected to reach $4.5 trillion by 2020 from $2.5 trillion in 2009) leads to improved quality in the delivery and outcomes, this correlation has not been demonstrated [1] . In an effort to improve the correlation between health care spending and quality, the Department of Health and Human Services (HHS) was directed by the Patient Protection and Affordable Care Act (PPACA, otherwise known as the ACA, enacted in March 2010) to expand its use of health care quality measures (including expanding its pay-for-performance programs). Despite the mandate for the implementation of quality measures by HHS, the process by which quality measures are identified, vetted, demonstrated and implemented is complex and continues to evolve. Mandatory reporting of quality measures was included in the ACA (section 2701), and in January 2012, the HHS announced the initial set of health care quality measures for Medicaid-eligible adults. These measures were evaluated by the Agency for Healthcare Research and Quality (AHRQ), and endorsed by the National Quality Forum (NQF, whose membership includes more than 400 organizations that represent health care providers, consumers, and researchers) [2] . Cancer measures were excluded from this group, since the ACA provided guidance on cancer quality measures separately in the Medicaid Quality Measurement Program (MQMP).
In patients with cancer, the ACA (section 3005) utilizes the freestanding cancer hospitals to be responsible for reporting cancerspecific quality measures. In 1983, Congress developed a system (defined as the Prospective Payment System, PPS) to control hospital costs charged to Medicare (now Centers for Medicare & Medicaid Services, CMS), but provided free-standing cancer hospitals an exemption to this system given their higher than average costs overall. While most care (including cancer care) is reimbursed as cumulative amount based on a "disease-related group" (DRG) payment, 11 freestanding cancer hospitals are paid on a fee-for-service basis (and are thus considered Prospective Payment System (PPS)-exempt). These 11 PPS-exempt cancer hospitals were required by the ACA to participate in the Prospective Payment System (PPS)-Exempt Hospitals Quality Reporting (PCHQR) program for cancer discharges, which mandates the public reporting of quality data in fiscal year 2014. The reporting period for the 2014 PCHQR began on January 1, 2013. Thus, the 11 PPS-exempt cancer hospitals began reporting 5 quality measures, which include two CDC National Health Safety Network health care associated infection outcome measures, one process of care measure for colon cancer, and two process of care measures for different types of breast cancer (Table 1) , all of which are endorsed by the NQF.
Given the early requirement for and familiarity with reporting quality measures by the 11 PPS-exempt cancer hospitals, we set out to determine whether the directors of the gynecologic oncology programs in the PPS-exempt cancer hospitals could agree upon reasonable and appropriate quality measures specific to the care of women with gynecologic cancers.
Methods
Given the absence of gynecologic cancer specific quality measures endorsed by the NQF, a list of 12 potential quality measures specific to the specialty of gynecologic oncology was developed by two of the authors (DEC and BAG). These quality measures were derived from a variety of sources, including some which were endorsed by the NQF (for general oncology), some ovarian cancer specific measures that were developed jointly between the Society of Gynecologic Oncology (SGO) and the American Society of Clinical Oncology (ASCO) as part of the ASCO Quality Outcome Practice Initiative (QOPI) but not yet endorsed by the NQF [3] , and others from the Quality and Outcomes Committee of the SGO ( Table 2 ). Measures already in use (for example, from the Physician Quality Reporting System (PQRS)) like perioperative antibiotic or thromboembolic prophylaxis were not included. In general, the selection of measures were chosen to span the most common gynecologic malignances, to account for the indicators that differentiates care provided to patients with gynecologic cancers, and to cover some general oncology measures that have been adopted by other organizations. This list was not meant to be comprehensive; it was designed to attempt to understand the factors that gynecologic oncologists believe define quality.
The compiled list was distributed to the directors or their designee (herein called "directors", all of whom are gynecologic oncologists) of gynecologic oncology programs at the 11 PPS-exempt hospitals (Table 3) . Directors were asked to rank the measures (with 1 being the "best" measure and 12 being the "worst" measure) without any specific guidance as to how this should be accomplished. There was no discussion amongst directors and specifically, these individuals were not explicitly asked to consider the origin of the measures, their complexity or feasibility of data collection, the reproducibility of these measures, or their implications on measuring quality outcomes. Recommendations for other measures not included in the initial list were also solicited. Descriptive statistics (including mean and SD for rankings) were utilized.
Results
Of the 12 quality measures distributed to the directors of gynecologic oncology programs at the PPS-exempt cancer hospitals, there was a wide variability in the rankings between directors ( Table 4 ). The quality measure ranked most highly (had the lowest ranking score) had a mean score of 3, with a standard deviation of 2.6. The measure that ranked lowest (had the highest score) had a mean score of 8.6, with a standard deviation of 2.8. The standard deviations ranged from 2.4 to 3.8, demonstrating a lack of agreement about the "best" measure in determining quality gynecologic cancer care. Despite this apparent lack of consensus, certain trends were apparent. When the distributed quality measures were considered based on the component of care responsible for assessment of the measure, it was more common for measures under the control of a provider (such as the documentation of residual disease after ovarian cancer surgery or offering minimally invasive surgery for endometrial cancer) to rank more highly than measures primarily determined by forces outside of the provider (such as patient satisfaction) or generally provided by other non-physician clinical staff (such as documentation of functional status or pain, Table 5 ). While the overall number of measures was limited, it seems that measures focusing on a specific malignancy were more highly ranked than general oncology measures (75% of the disease specific measures were ranked amongst the top 4 measures, Table 5 ). Furthermore, there were four measures suggested by the directors (which were not initially provided to the directors for their consideration); two were cervical cancer specific and provider-focused (offering fertility-sparing surgery and documenting the recommendation for concurrent chemotherapy with radiation), while the other two were general oncology measures (perioperative morbidity and progression-free survival).
Given that each of the divisions of gynecologic oncology at the PPS-exempt cancer hospitals are in academic settings, no associations can be drawn about the impact of physician practice type on the rankings of quality measures. However, three of the 11 directors reported that the compensation of their faculty is at least partially linked to quality outcomes (including patient satisfaction scores, rate of thromboembolism prophylaxis, and on-time operating room starts). Again, given the small sample size, the impact of a specific remuneration system on the ranking of quality measures cannot be assessed. Across all of the 11 hospitals, the percent Medicare beneficiaries that make up their gynecologic oncology practice ranged from 5 to 60% (average 40%), thereby limiting the ability to draw conclusions as to the impact of patient insurance status on the ranking of quality measures.
Discussion
Despite the mandate for PPS-exempt cancer hospitals to report quality measures on January 1, 2013, there is wide variability in institutional ranking of quality measures, and may relate to provider or institutional factors. While there are no specific gynecologic cancer quality measures endorsed by the National Quality Forum to date, there will be increasing importance on the development, validation and implementation of such measures in the future. Currently, the only measures to distinguish quality surgical care for gynecologic cancer patients are appropriate thromboembolic and antibiotic prophylaxis. The Affordable Care Act (ACA) has mandated the reporting of cancer quality measures by the 11 PPS-exempt cancer hospitals for fiscal year 2014, and the expectation will be that this will extend beyond these select institutions soon thereafter. Given the rapid expansion of cost of healthcare without a commensurate improvement in the quality of the care delivered, attention to the definition of quality is imperative if payment for cancer care will eventually be tied to performance. In fact, the ACA required that 1% of Medicare hospital payments be withheld in fiscal year 2012 under pay for performance in the Medicare Value-Based Purchasing Program; this withholding will rise to 2% by 2017 (increasing by 0.25% per year) and will be used to reward hospitals for the quality of the care they provide to Medicare beneficiaries [4] . Given that a pay for performance strategy was shown to decrease mortality in England [5] , expansion of such initiatives in the United States is expected to be forthcoming. While generic quality measures are easy to report, they do not explicitly represent opportunities for improvements in cancer care especially for the gynecologic cancer population [6] . As such, participation in quality improvement programs such as the Center for Medicare & Medicaid Services (CMS) Physician Quality Reporting (PQRS), the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative (QOPI), and the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) may have overall benefits in quality improvement, but may not be entirely relevant to practice in gynecologic oncology. Given the fact that outcomes in ovarian cancer are directly related to surgeon experience and higher hospital volume [7, 8] , defining, validating and receiving NQF endorsement for measures of quality ovarian cancer care are critical. Given that it is estimated that more than half of all ovarian cancer patients receive care from less-experienced surgeons and lower-volume hospitals, timely identification of such quality measures may lead to more women receiving adequate ovarian cancer care, resulting in improved outcomes.
The development of quality measures for gynecologic cancers is currently in its infancy. The Society of Gynecologic Oncology has several ongoing quality and outcome improvement initiatives with organizations dedicated to health care quality, and specific gynecologic cancer measures (such as cost, surgical and perioperative complications and morbidity, toxicity associated with non-surgical treatments, patient satisfaction, and survival) are being developed and tested [3] . The recent SGO Practice Summit entitled "We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies" [9] highlights the importance of the development of quality measures specific to the practice of gynecologic Table 2 Proposed quality measures that impact gynecologic cancer care (listed alphabetically).
Debulking: documentation of debulking status (optimal versus suboptimal)
in the operative note of a patient undergoing surgery for advanced ovarian cancer 2. Function: documentation of functional status at every outpatient encounter 3. GCSF: adherence to ASCO guidelines for the use of GCSF in the prevention of chemotherapy-induced neutropenia 4. Hospice: documentation of discussion of or referral to hospice within 30 days of death 5. Intraperitoneal: documentation of discussion of intraperitoneal chemotherapy for patients with advanced ovarian cancer 6. Minimally invasive surgery: documentation of a discussion regarding the possibility of minimally invasive surgery for the surgical management of clinical stage I-II endometrial cancer (including documentation of offer for referral to a provider who performs this surgery) 7. Pain: documentation of pain status at every outpatient encounter 8. Readmission: readmission of gynecologic cancer patients within 30 days of discharge 9. Referral: documentation of referral to or consultation with a gynecologic oncologist consistent with ACOG/SGO committee opinion for the "role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer" 10. Satisfaction: patient satisfaction scores are reviewed and tracked at the provider level 11. Survival: gynecologic cancer survival is tracked by stage 12. Tumor board: discussion of all gynecologic cancer cases at multi-disciplinary tumor board Table 3 Prospective Payment System (PPS)-exempt cancer hospitals (listed alphabetically).
Table 4
Ranking of quality measures in Prospective Payment System (PPS)-exempt cancer programs (sorted alphabetically by name of quality measure), with hospital names removed. Debulking  1  1  8  2  2  1  1  6  1  7  3  Functional status  8  11  9  10  12  11  11  4  9  3  10  GCSF  3  12  11  7  11  12  12  7  10  6  6  hospice  7  9  3  8  7  7  9  3  11  10  7  Intraperitoneal  4  7  9  1  6  2  7  12  4  8  2  M I S  2  4  6  3  3  4  4  2  5  1 1  1 1  Pain  9  10  2  9  10  5  10  11  3  2  8  Readmission  10  8  7  12  8  9  8  1  6  4  9  Referral  11  2  10  6  1  6  2  10  8  12  4  Satisfaction  6  5  5  11  5  8  5  9  7  5  12  Survival  5  3  1  5  4  3  3  8  12  1  1  Tumor board  12  6  4  4  9  10  6  5  2  9  5 oncology, and calls for the establishment of a national gynecologic cancer registry to begin collecting the data necessary for more robust identification of indicators of quality that can be utilized for future benchmarking. Currently, the SGO quality and outcomes committee is evaluating potential quality measures in endometrial, ovarian and cervical cancers that will be tested in the future. The process of selecting potential measures has been based on that used by the NQF Steering Committee and Technical panels, which used four criteria: importance (the extent to which a measure reflects variation and thus has the potential for improvement), scientific acceptability (a measure that is reliable, valid, precise, and adaptable to patient preference), usability (ensuring that information produced as part of the measure could be used to make decisions and/or take actions) and feasibility (confirming that data can be obtained within normal clinical care and that implementation of the measure is achievable).
Given that the quality measures ranked in this study were evaluated only by academic practices in PPS exempt cancer hospitals, no conclusions can be drawn as to the impact of physician practice on the importance of specific quality measures. In addition, the finding that directors of gynecologic oncology programs at these hospitals ranked measures under the control of the provider more highly than others cannot be generalized to indicate that these types of measures should be evaluated for potential endorsement in the future. These results do, however, highlight the importance of beginning the conversation about quality gynecologic cancer care within the specialty, and the need to be fully engaged in thinking about the factors that contribute to the delivery of quality care. In summary, while the importance of quality gynecologic cancer care is widely recognized as the means by which patients will receive optimal care, the current state of knowledge regarding the specific measures that are important to gynecologic oncologists is less clear. Despite mandatory reporting of some quality measures by PPS-exempt cancer hospitals, it is imperative that discussions amongst providers of gynecologic cancer continue towards the creation of national registries that can begin to define important quality measures. 
